![]() ![]() In India Consumer Healthcare (ICH), the company added 10 new products and 11 new SKUs launched in H1FY23. The company launched three products during H1FY23 including a Pre-Filled Syringe (PFS) in Germany and eight SKUs expected to be launched in various targeted markets in Q3FY23 based on a tender calendar. The pharma major also reported strong Inhalation Anesthesia (IA) sales in the US market with continued volume growth driving market share gains. We continue to make investments to drive growth in these businesses,” Nandini Piramal, Chairperson, Piramal Pharma Limited said in a statement. We have the vision to grow all our businesses to a significant scale over the medium term and have strong growth levers in place for each of them. Historically we have had a greater skew of sales and profits in the second half of the year and this year is no different. We expect to deliver a much-improved performance in the second half of the current financial year. For the quarter and a half year that ended September 2022, our business has delivered a resilient performance despite multiple internal and external challenges. Over the last 10 years, we have made several strategic choices that have helped nurture and scale our business and establish Piramal Pharma (PPL) as a leading global pharmaceuticals player. “We announce our first results post demerger as an independent and focused pharma company.
0 Comments
Leave a Reply. |